Ken Griffin Hcw Biologics Inc. Transaction History
Citadel Advisors LLC
- $483 Billion
- Q2 2024
A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Hcw Biologics Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 13,876 shares of HCWB stock, worth $7,076. This represents 0.0% of its overall portfolio holdings.
Number of Shares
13,876Holding current value
$7,076% of portfolio
0.0%Shares
2 transactions
Others Institutions Holding HCWB
# of Institutions
20Shares Held
1.21MCall Options Held
0Put Options Held
0-
Avantax Planning Partners, Inc.280KShares$142,5650.01% of portfolio
-
High Tower Advisors, LLC Chicago, IL181KShares$92,2130.0% of portfolio
-
Geode Capital Management, LLC Boston, MA170KShares$86,8960.0% of portfolio
-
Cresset Asset Management, LLC Chicago, IL132KShares$67,3140.0% of portfolio
-
Pullen Investment Management, LLC Bradenton, FL85.1KShares$43,4090.05% of portfolio
About HCW Biologics Inc.
- Ticker HCWB
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 35,833,100
- Market Cap $18.3M
- Description
- HCW Biologics Inc., a preclinical stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and age-related diseases. The company's lead products include HCW9218, which is an injectable immunotherapeutic for patients with pancreatic, ovarian, breast, prostate, and colorectal...